F. Bonnetain

发表

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review

X. Pivot, C. Borg, F. Fiteni, 2014, Cancer medicine.

Predictors of long-term functional outcome and health-related quality of life after out-of-hospital cardiac arrest.

É. Marijon, J. Empana, J. Mira, 2017, Resuscitation.

Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Franck Bonnetain, Maryse Fiche, William Jacot, 2014, Critical reviews in oncology/hematology.

Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.

D. Papathanassiou, F. Bonnetain, C. Schvartz, 2012, The Journal of clinical endocrinology and metabolism.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

David Goldstein, Florence Huguet, Franck Bonnetain, 2016, JAMA.

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review

C. Bascoul-Mollevi, F. Cottone, F. Fiteni, 2019, Quality of Life Research.

Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies.

F. Bonnetain, D. Caillot, A. Anota, 2016, Annales pharmaceutiques francaises.

Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival.

G. Hédelin, P. Arveux, F. Bonnetain, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Estimating the cost related to surveillance of colorectal cancer in a French population

M. Abrahamowicz, C. Lejeune, C. Bonithon-Kopp, 2009, The European Journal of Health Economics.

RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study☆

F. Collin, P. Maingon, J. Thariat, 2019, EBioMedicine.

Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration

D. Sargent, T. Yamanaka, I. Floriani, 2014, Forum of clinical oncology.

Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy

P. Validire, P. Rougier, J. Emile, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine DefectiveMismatchRepair Status asaPrognosticBiomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy

P. Validire, P. Rougier, J. Emile, 2011 .

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Bernard Leduc, Franck Bonnetain, Olivier Bouché, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?

L. Collette, G. Calais, T. Conroy, 2012, European journal of cancer.

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

B. Chauffert, J. Bosset, P. Maingon, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The effects of work factors on nurses’ job satisfaction, quality of care and turnover intentions in oncology

N. Gillet, E. Fouquereau, L. Moret, 2018, Journal of advanced nursing.

Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study

S. Suissa, F. Bonnetain, S. Dell'aniello, 2012, Breast Cancer Research and Treatment.

Dehydroepiandrosterone up-regulates the Adrenoleukodystrophy-related gene (ABCD2) independently of PPARalpha in rodents.

T. Pineau, J. Bellenger, F. Bonnetain, 2007, Biochimie.

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study

G. Choukroun, C. Legendre, D. Vernerey, 2019, Trials.

Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.

J. Cercueil, R. Loffroy, C. Lepage, 2018, Journal of hepatology.

Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology

G. Collins, K. Van Steen, D. Cella, 2019, Quality of Life Research.

Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial.

W. Scheithauer, F. Bonnetain, A. de Gramont, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nutritional Status Affects Treatment Tolerability and Survival in Metastatic Colorectal Cancer Patients: Results of an AGEO Prospective Multicenter Study

J. Sabate, F. Bonnetain, J. Taieb, 2012, Oncology.

Preoperative radiochemotherapy for resectable localised oesophageal cancer: a controversial strategy.

B. Chauffert, P. Maingon, F. Ghiringhelli, 2010, Critical reviews in oncology/hematology.

Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review

C. Tournigand, F. Bonnetain, A. de Gramont, 2015, Therapeutic advances in medical oncology.

Survival end point reporting in randomized cancer clinical trials: a review of major journals.

S. Mathoulin-Pélissier, F. Bonnetain, S. Gourgou-Bourgade, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer.

P. Arveux, F. Bonnetain, S. Causeret, 2011, The oncologist.

Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: the METAL3 Study.

F. Dalenc, F. Bonnetain, T. Filleron, 2015, Contemporary clinical trials.

Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials

F. Fiteni, M. Paillard, F. Bonnetain, 2017, Expert review of anticancer therapy.

Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review

F. Fiteni, F. Bonnetain, V. Westeel, 2016, BMC Cancer.

Time-to-event endpoints reporting in operable non-small-cell lung cancer randomized clinical trials: A systematic review

F. Fiteni, M. Paillard, F. Bonnetain, 2016 .

An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?

L. Collette, G. Calais, T. Conroy, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

P. Validire, F. Bonnetain, P. Hammel, 2015, BMC Cancer.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

J. Taïeb, D. Vernerey, F. Bonnetain, 2016, Journal of the National Cancer Institute.

Attempts to improve locoregional chemotherapy for the prevention of colonic cancer liver metastasis in the rat.

B. Chauffert, F. Bonnetain, P. Rat, 2006, Gastroenterologie clinique et biologique.

Platinum-sensitivity in metastatic colorectal cancer: towards a definition.

C. Tournigand, F. Bonnetain, A. Larsen, 2013, European journal of cancer.

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

M. Ducreux, P. Rougier, O. Bouché, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

F. Bonnetain, C. Chouaid, J. Bennouna, 2017, Oncology.

Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.

C. Borg, C. Mariette, F. Fiteni, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C

F. Guillemin, T. Conroy, C. Rotonda, 2008, Quality of Life Research.

Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years

P. Arveux, F. Bonnetain, L. Arnould, 2010, BMC Cancer.

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial

T. Conroy, M. Déjardin, J. Bosset, 2004 .

Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

B. Chauffert, C. Lepage, A. Denys, 2014, Alimentary pharmacology & therapeutics.

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy

X. Pivot, C. Borg, F. Fiteni, 2014, BMC Gastroenterology.

Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer

B. Chauffert, F. Bonnetain, S. Causeret, 2010, Archives of Gynecology and Obstetrics.

B. Milleron, O. Molinier, G. Zalcman, 2016, European Respiratory Journal.

Reply to Sorscher S.

F. Fiteni, F. Bonnetain, 2017, Breast.

Report on the First Stages in the Translation of Measures of Health-Related Quality of Life at the End of Life

S. Villet, F. Bonnetain, N. Baize, 2014 .

FactorsAssociatedWithFatigueAfter Surgery inWomenWith Early-Stage InvasiveBreastCancer

F. Guillemin, F. Bonnetain, eMICHEL Velten, 2013 .

Quality of life and attitudes towards psychotropics and dependency: consumers vs. non‐consumers aged 50 and over

F. Alla, S. Briançon, F. Bonnetain, 2004, Journal of clinical pharmacy and therapeutics.

Modeling strategies to improve estimates of prognostic factor analyses with patient reported outcomes in oncology

G. Collins, D. Cella, F. Cottone, 2018 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Prognostic Value of Angiopoietin-2 for Death Risk Strati ﬁ cation in Patients with Metastatic Colorectal Carcinoma CancerEpidemiology,Biomarkers&Prevention

C. Borg, F. Ghiringhelli, D. Vernerey, 2015 .

[Assessment of the quality of life with regard to health following a cancer diagnosis].

F. Bonnetain, G. Mouillet, S. Paget‐Bailly, 2017, Revue de l'infirmiere.

F. Fiteni, F. Bonnetain, N. Isambert, 2019, BMC Cancer.

Randomized Trial Assessing the Impact of Routine Assessment of Health-Related Quality of Life in Patients with Head and Neck Cancer

P. Maingon, F. Bonnetain, S. Maillard, 2021, Cancers.

Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma

B. Chauffert, J. Cercueil, R. Loffroy, 2009, American journal of clinical oncology.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

M. Moore, D. Goldstein, D. Vernerey, 2016, British Journal of Cancer.

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

B. Chauffert, J. Honnorat, D. Frappaz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer

C. Borg, F. Ghiringhelli, Thierry Nguyen, 2014, Cancer Chemotherapy and Pharmacology.

[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].

B. Chauffert, P. Maingon, P. Rougier, 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial.

T. Conroy, J. Bosset, O. Bouché, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

497OBEVACIZUMAB-ERLOTINIB AS MAINTENANCE THERAPY IN METASTATIC COLORECTAL CANCER. FINAL RESULTS OF THE GERCOR DREAM STUDY.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer : A gercor randomized open-label phase III study.

C. Tournigand, P. Laurent-Puig, F. Bonnetain, 2014 .

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC).

C. Tournigand, F. Bonnetain, A. de Gramont, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.

M. Loriot, P. Laurent-Puig, C. Lepage, 2013 .

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.

J. Bosset, C. Borg, Stefano Kim, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.

F. Fein, F. Bonnetain, J. Taieb, 2012 .

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of Clinical Oncology.

LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial.

P. Laurent-Puig, P. Quirke, D. Vernerey, 2015 .

PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer--A GERCOR Study.

F. Bonnetain, P. Hammel, A. Gramont, 2015 .

Malnutrition Is High and Underestimated During Chemotherapy in Gastrointestinal Cancer: An AGEO Prospective Cross-Sectional Multicenter Study

J. Sabate, F. Bonnetain, J. Taieb, 2012, Nutrition and cancer.

Surrogate end points for overall survival in breast cancer trials: A review.

F. Fiteni, F. Bonnetain, 2016, Breast.

S. Msika, C. Mariette, G. Piessen, 2019, Annals of surgery.

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

I. Sobhani, P. Laurent-Puig, F. Bonnetain, 2013, British Journal of Cancer.

An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma

X. Paoletti, J. Cercueil, F. Bonnetain, 2016, BMJ Open.

F. Bonnetain, C. Touboul, G. Saba, 2019, Clinical lymphoma, myeloma & leukemia.

Evaluation of quality of life after breast reconstruction using an autologous latissimus dorsi myocutaneous flap.

F. Bonnetain, C. Loustalot, S. Dabakuyo, 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma.

F. Végran, R. Boidot, S. Lizard-Nacol, 2011, Endocrine-related cancer.

The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas

C. Borg, C. Mariette, F. Ghiringhelli, 2015, Journal of Hematology & Oncology.

Relation between long-term blood pharmacokinetics (PK), pharmacogenomics (PG), and severe neurotoxicity in patients undergoing an oxaliplatin (O)-based regimen.

M. Hebbar, F. Bonnetain, A. de Gramont, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative Chemoradiotherapy (CT-RT) Improves Local Control in T3-4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial

T. Conroy, O. Bouché, P. Romestaing, 2005 .

Quality of life after out-of-hospital cardiac arrest: The parisian registry

J. Empana, A. Cariou, G. Geri, 2015, Intensive Care Medicine Experimental.

Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.

D. Goldstein, N. Spry, D. Vernerey, 2014 .

Prognosis of hepatocellular carcinoma (HCC): Comparison of four staging systems in two French clinical trials

X. Paoletti, P. Rougier, O. Bouché, 2007 .

Multicenter randomized phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients

O. Bouché, F. Bonnetain, L. Bedenne, 2005 .

Parenteral nutrition at the palliative phase of advanced cancer: the ALIM-K study protocol for a randomized controlled trial

L. Pazart, F. Bonnetain, C. Bouleuc, 2014, Trials.

F. Bonnetain, M. Mercier, A. Poirier, 2012, Trials.

A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer.

T. Conroy, P. Arveux, C. Mariette, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

J. Blay, S. Litière, J. Verweij, 2018, OncoTarget.

Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.

P. Rougier, V. Boige, O. Bouché, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

F. Penault-Llorca, F. Bonnetain, L. Arnould, 2006, British Journal of Cancer.

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

L. Collette, M. Piccart, M. Taphoorn, 2016, The Lancet. Oncology.

Erratum to: Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

P. Vandel, P. Manckoundia, D. Vernerey, 2016, BMC Geriatrics.

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

P. Vandel, D. Vernerey, F. Bonnetain, 2016, BMC Geriatrics.

Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.

I. Sobhani, J. Taïeb, F. Bonnetain, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

C. Tournigand, W. Scheithauer, D. Vernerey, 2015, The Lancet. Oncology.

Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.

X. Paoletti, O. Bouché, F. Bonnetain, 2015, The oncologist.

Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials.

F. Fiteni, F. Bonnetain, F. Efficace, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.

X. Paoletti, P. Rougier, O. Bouché, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Vincenzo Valentini, Philippe Lambin, Laurence Collette, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.

T. Conroy, C. Mariette, O. Bouché, 2015, European journal of cancer.

Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study.

B. Chauffert, J. Bosset, P. Rougier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration‐resistant prostate cancer

F. Bonnetain, E. Barret, D. Prapotnich, 2018, BJU international.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.

F. Ghiringhelli, S. Ladoire, F. Bonnetain, 2011, The oncologist.

The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry

T. Petrella, F. Bonnetain, R. Casasnovas, 2015, Leukemia & lymphoma.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Effect of dietary polyunsaturated fatty acids on the expression of peroxisomal ABC transporters.

J. Chardigny, J. Bellenger, F. Bonnetain, 2008, Biochimie.

Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trial

S. Msika, C. Mariette, G. Piessen, 2011, BMC Cancer.

Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer

S. Msika, C. Mariette, G. Piessen, 2019, The New England journal of medicine.

French Intensive Care Society, International congress – Réanimation 2016

Paul P. Tallon, Stéphane Huot, B. Souweine, 2016, Annals of Intensive Care.

C. Tournigand, R. Labianca, J. Ajani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of baseline seric Syndecan‐1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

C. Borg, O. Bouché, F. Ghiringhelli, 2016, International journal of cancer.

Patients’ perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study

X. Paoletti, C. Flahault, F. Bonnetain, 2017, European journal of cancer care.

Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy

J. Taïeb, F. Bonnetain, D. Malka, 2011, Cancer.

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

C. Coutant, P. Fumoleau, F. Bonnetain, 2013, Breast.

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

C. Tournigand, G. Deplanque, F. Bonnetain, 2019, International journal of oncology.

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

N. Girard, O. Molinier, P. Souquet, 2016, Lung cancer.

Third‐line systemic treatment for non‐small cell lung cancer

L. Trinquart, Stefano Kim, F. Bonnetain, 2014 .

615O_PRHybrid minimally invasive vs. open esophagectomy for patients with esophageal cancer: Long-term outcomes of a multicenter, open-label, randomized phase III controlled trial, the MIRO trial

C. Mariette, G. Piessen, D. Pezet, 2017 .

Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicenter, open-label, randomized phase III controlled trial, the MIRO trial.

C. Mariette, G. Piessen, D. Pezet, 2015 .

Predictive value of neutrophils count for local tumor control after chemoradiotherapy in patients with locally advanced pancreatic carcinoma.

P. van Houtte, D. Goldstein, A. Schernberg, 2021, International journal of radiation oncology, biology, physics.

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results

B. Chauffert, T. Conroy, C. Bascoul-Mollevi, 2020, Quality of Life Research.

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial

C. Tournigand, F. Bonnetain, P. Hammel, 2019, Cancer medicine.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

R. Labianca, H. Friess, J. Berlin, 2018, The Lancet. Oncology.

Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial

F. Bonnetain, P. Hammel, C. Neuzillet, 2015, Trials.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

P. Validire, F. Bonnetain, P. Hammel, 2015, BMC Cancer.

F. Fiteni, D. Vernerey, F. Bonnetain, 2015, Expert review of anticancer therapy.

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

F. Fein, F. Bonnetain, J. Taieb, 2015, PloS one.

FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.

E. Raymond, P. Ruszniewski, F. Bonnetain, 2012, World journal of gastroenterology.

Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.

M. Ychou, P. Rougier, F. Bonnetain, 2010, European journal of cancer.

Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.

Thomas Filleron, Murielle Mauer, Simone Mathoulin-Pélissier, 2013, European journal of cancer.

Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.

C. Tournigand, F. Bonnetain, A. Larsen, 2011, The oncologist.

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).

X. Causse, P. Rougier, F. Caroli-Bosc, 2008, European journal of cancer.

Overexpression of Caspase-3s Splice Variant in Locally Advanced Breast Carcinoma Is Associated with Poor Response to Neoadjuvant Chemotherapy

Franck Bonnetain, F. Végran, R. Boidot, 2006, Clinical Cancer Research.

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

P. Bachellier, C. Borg, D. Vernerey, 2016, BMC Cancer.

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

J. Taïeb, V. Boige, M. Hebbar, 2013, Journal of hepatology.

Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

Franck Bonnetain, Boris Guiu, Sylvain Ladoire, 2009, Gut.

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

B. Asselain, L. Mauriac, P. Fumoleau, 2011, British Journal of Cancer.

D. Vernerey, F. Bonnetain, G. Mouillet, 2019, Health and Quality of Life Outcomes.

In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?

P. Febbo, X. Pivot, S. Butler, 2014, The oncologist.

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

F. Penault-Llorca, R. Boidot, P. Fumoleau, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.

E. Assenat, A. Bertaut, F. Bonnetain, 2017 .

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

F. Penault-Llorca, P. Fumoleau, S. Ladoire, 2010, British Journal of Cancer.

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

P. Auquier, C. Bascoul-Mollevi, C. Borg, 2013, Quality of Life Research.

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

X. Pivot, B. Degano, D. Vernerey, 2017, BMC Cancer.

Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study

F. Pruvot, M. Hebbar, F. Bonnetain, 2013, Journal of chemotherapy.

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S. Sleijfer, F. Collin, M. van Glabbeke, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

J. Taïeb, F. Fein, F. Bonnetain, 2014, European journal of cancer.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

S Michiels, B Asselain, J Bogaerts, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review

F. Cottone, F. Bonnetain, A. Brédart, 2018, Health and Quality of Life Outcomes.

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

C. Coutant, P. Fumoleau, F. Ghiringhelli, 2011, The Journal of pathology.

Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001–02 trial). Results of a planned interim analysis

F. Bonnetain, J. Jouve, M. Gasmi, 2008 .

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma

C. Borg, C. Mariette, F. Fiteni, 2016, Cancer medicine.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

T. Conroy, P. Arveux, C. Mariette, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of health‐related quality of life for death risk stratification in patients with unresectable glioblastoma

B. Chauffert, F. Ducray, D. Frappaz, 2016, Cancer medicine.

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

B. Milleron, J. Trédaniel, G. Zalcman, 2016, European journal of cancer.

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

F. Fein, F. Bonnetain, J. Taieb, 2016, Quality of Life Research.

Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study

C. Tournigand, F. Bonnetain, A. de Gramont, 2014, Health and Quality of Life Outcomes.

The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma.

X. Paoletti, O. Bouché, F. Bonnetain, 2013, Journal of hepatology.

Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials

X. Paoletti, P. Rougier, S. Collette, 2008, Quality of Life Research.

Patient‐reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes

G. Abel, M. Sprangers, M. Vignetti, 2018, Cancer.

[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved].

C. Haie-meder, P. Arveux, I. Ray-Coquard, 2012, Bulletin du cancer.

Conservative treatment of early glottic carcinomas with exclusive radiotherapy.

I. Barillot, J. Horiot, J. Thariat, 2004, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

MiR 31 3p as a predictive biomarker of cetuximab efficacy effect in metastatic colorectal cancer (mCRC) patients enrolled in FIRE-3 study.

P. Laurent-Puig, V. Heinemann, F. Bonnetain, 2016 .

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

D. Arsène, P. Rougier, B. Buecher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer

F. Bonnetain, A. Larsen, A. Gramont, 2013, Current Colorectal Cancer Reports.

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

C. Tournigand, F. Bonnetain, P. Hammel, 2017, The lancet. Gastroenterology & hepatology.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

C. Tournigand, P. Laurent-Puig, F. Bonnetain, 2015, BMC Cancer.

F. Guillemin, T. Conroy, C. Rotonda, 2011, Contemporary clinical trials.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

C. Tournigand, C. Borg, O. Bouché, 2017, Journal of the National Cancer Institute.

Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma

C. Borg, O. Bouché, F. Ghiringhelli, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer

V. Jooste, J. Faivre, F. Bonnetain, 2008, Cancer.

Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102.

P. Maingon, F. Bonnetain, X. Mirabel, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proceedings of Réanimation 2017, the French Intensive Care Society International Congress

K. Tarte, G. Le Roux, D. Boels, 2017, Annals of Intensive Care.

EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors.

H. Wildiers, M. Aapro, A. Ring, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial

J. Limacher, C. Rotonda, F. Bonnetain, 2015, PloS one.

QoLR: An R Package for the Longitudinal Analysis of Health-Related Quality of Life in Oncology

Amélie Anota, Franck Bonnetain, M. Savina, 2017 .

C. Rotonda, F. Chauvin, F. Bonnetain, 2017, British Journal of Cancer.

Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.

P. Maingon, P. Arveux, P. Fumoleau, 2013, European journal of cancer care.

The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers

S. Msika, T. Conroy, M. Copin, 2018, BMC Cancer.

Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup

A. Eschalier, N. Kerckhove, J. Busserolles, 2019, BMJ Open.

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

D. Planchard, P. Souquet, F. Bonnetain, 2019, Journal of cachexia, sarcopenia and muscle.

Factors associated with fatigue after surgery in women with early-stage invasive breast cancer.

F. Guillemin, T. Conroy, C. Rotonda, 2013, The oncologist.

Evaluation of efficacy and efficiency of a pragmatic intervention by a social worker to support informal caregivers of elderly patients (The ICE Study): study protocol for a randomized controlled trial

C. Lejeune, F. Bonnetain, S. Dabakuyo, 2016, Trials.

Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patients

F. Guillemin, T. Conroy, C. Bascoul-Mollevi, 2012, Health and Quality of Life Outcomes.

Phase II/III randomized trial of exclusive chemoradiotherapy with or without dose escalation in locally advanced esophageal carcinoma: The CONCORDE study (PRODIGE 26).

D. Peiffert, F. Bonnetain, J. Seitz, 2016 .

Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report

E. Van Cutsem, T. Seufferlein, P. Rougier, 2017, Cancers.

Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial

C. Lavergne, T. Conroy, C. Bascoul-Mollevi, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study

C. Bascoul-Mollevi, F. Bonnetain, S. Gourgou-Bourgade, 2014, Health and Quality of Life Outcomes.

Gastric signet ring cell carcinoma: how to investigate its impact on survival.

C. Mariette, G. Piessen, F. Bonnetain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials

F. Bonnetain, Z. Hamidou, T. S. Dabakuyo, 2011, Expert review of pharmacoeconomics & outcomes research.

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.

C. Lombard-Bohas, O. Bouché, F. Bonnetain, 2009, European journal of cancer.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Response shift effects on measuring post-operative quality of life among breast cancer patients: a multicenter cohort study

F. Guillemin, T. Conroy, F. Bonnetain, 2013, Quality of Life Research.

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.

Daniel J Sargent, Qian Shi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA29Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial

E. Assenat, A. Bertaut, F. Bonnetain, 2017 .

Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study.

D. Goldstein, F. Bonnetain, B. Glimelius, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

T. Conroy, P. Rougier, P. Arveux, 2005, Gastroenterologie clinique et biologique.

Surrogate endpoints for overall survival in lung cancer trials: a review

F. Fiteni, F. Bonnetain, V. Westeel, 2017, Expert review of anticancer therapy.

Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology.

Gilles Créhange, Alexandre Cochet, Paul M Walker, 2011, International journal of radiation oncology, biology, physics.

Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.

J. Lemonnier, M. Lacroix-Triki, H. Bonnefoi, 2022, Journal of Clinical Oncology.

Psychometric validation of the French version of the Supportive Care Needs Survey for Partners and Caregivers of cancer patients

C. Mariette, V. Christophe, F. Bonnetain, 2018, European journal of cancer care.

Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT‐C33) and specific complementary outpatient module (EORTC OUT‐PATSAT7)

N. Aaronson, T. Conroy, W. Chie, 2018, European journal of cancer care.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Karin Haustermans, Simone Mathoulin-Pélissier, Julien Taieb, 2014, European journal of cancer.

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial

A. Luciani, I. Sobhani, K. Leroy, 2015, BMC Cancer.

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

O. Bouché, F. Bonnetain, J. Taieb, 2017, Oncotarget.

The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

Y. Bécouarn, O. Bouché, F. Bonnetain, 2016 .

Predictive value of health-related quality of life on radiotherapy-related toxicities in patients with head and neck cancer

P. Maingon, F. Bonnetain, S. Maillard, 2022, Supportive Care in Cancer.

F. Bonnetain, 2010, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.

I. Salmon, J. Vaillant, A. Sauvanet, 2013, European journal of cancer.

Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.

I. Salmon, P. Rougier, J. Vaillant, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.

F. Bonnetain, O. Hentic, B. Landi, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

H. Wildiers, J. Bogaerts, J. Yarnold, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials

L. Collette, M. Piccart, M. Taphoorn, 2018, Clinical trials.

Impact of sentinel node biopsy on long-term quality of life in breast cancer patients

C. Coutant, P. Arveux, F. Bonnetain, 2013, British Journal of Cancer.

The influence of socio-economic and surveillance characteristics on breast cancer survival: a French population-based study

P. Arveux, F. Bonnetain, P. Grosclaude, 2008, British Journal of Cancer.

X. Pivot, B. Degano, D. Vernerey, 2017, BMC Cancer.

Clinical Relevance of Alternative Endpoints in Colorectal Cancer First‐Line Therapy With Bevacizumab: A Retrospective Study

M. Hebbar, F. Bonnetain, A. Hollebecque, 2017, Clinical colorectal cancer.

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC)

C. Lombard-Bohas, O. Bouché, F. Bonnetain, 2005 .

Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial

S. Mathoulin-Pélissier, F. Bonnetain, C. Bellera, 2016, BMC Cancer.

International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer

P. Fayers, S. Wheelwright, W. Chie, 2013, British Journal of Cancer.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

C. Porta, A. Ravaud, V. Flamand, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

F. Bonnetain, L. Bedenne, N. Methy, 2010, BMC Cancer.

Image-guided IMRT for localized prostate cancer with daily repositioning: inferring the difference between planned dose and delivered dose distribution.

P. Maingon, A. Arnaud, F. Bonnetain, 2014, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

Endpoints in cancer clinical trials.

X. Pivot, C. Borg, F. Fiteni, 2014, Journal of visceral surgery.

Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer.

P. Lambin, L. Collette, J. Bosset, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial

S. Mathoulin-Pélissier, F. Bonnetain, C. Bellera, 2016, BMC Cancer.

International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.

R. Labianca, L. Collette, D. Aust, 2012 .

The European organization for research and treatment of cancer — satisfaction with cancer care questionnaire: revision and extended application development

N. Aaronson, T. Conroy, W. Chie, 2017, Psycho-oncology.

Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE)

J. Bosset, E. Brain, F. Bonnetain, 2017, BMC Cancer.

Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.

Alexandre Cochet, Franck Bonnetain, P. Maingon, 2011, International journal of radiation oncology, biology, physics.

RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.

P. Laurent-Puig, H. Blons, O. Bouché, 2017 .

The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer

F. Guillemin, T. Conroy, A. Omorou, 2018, Cancer.

Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis

C. Porta, A. Ravaud, V. Flamand, 2015 .

A. Luciani, I. Sobhani, K. Leroy, 2015, BMC Cancer.

Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).

C. Tournigand, D. Vernerey, F. Bonnetain, 2017 .

2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)

C. Tournigand, F. Bonnetain, P. Hammel, 2015 .

Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review

F. Fiteni, F. Bonnetain, V. Westeel, 2016, BMC Cancer.

A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection.

P. Arveux, F. Bonnetain, S. Gouy, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus

T. Conroy, C. Mariette, O. Bouché, 2008 .

Maintenance therapy for advanced non-small cell lung cancer (NSCLC)

L. Trinquart, F. Bonnetain, D. Pérol, 2019, Cochrane Database of Systematic Reviews.

Maintenance therapy for advanced non‐small cell lung cancer (NSCLC)

L. Trinquart, F. Bonnetain, D. Pérol, 2015 .

Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX.

F. Bonnetain, L. Mineur, F. Di Fioré, 2016, European journal of cancer.

Intensity-modulated radiation therapy in head and neck cancer: prescribed dose, clinical challenges and results.

P. Maingon, F. Bonnetain, G. Créhange, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.

X. Paoletti, P. Rougier, C. Lombard-Bohas, 2011, Journal of hepatology.

Ethical leadership, professional caregivers' well-being, and patients' perceptions of quality of care in oncology.

N. Gillet, E. Fouquereau, L. Moret, 2018, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Christophe Tournigand, Franck Bonnetain, Olivier Dupuis, 2016, Cancer medicine.

The role of trait emotional intelligence in quality of life, anxiety and depression symptoms after surgery for esophageal or gastric cancer: A French national database FREGAT

C. Mariette, G. Piessen, V. Christophe, 2019, Psycho-oncology.

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

C. Tournigand, W. Scheithauer, F. Bonnetain, 2015 .

B. Chauffert, J. Honnorat, D. Frappaz, 2014 .

Propensity score methods and regression adjustment for analysis of nonrandomized studies with health‐related quality of life outcomes

G. Collins, F. Cottone, F. Bonnetain, 2019, Pharmacoepidemiology and drug safety.

Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time

F. Guillemin, T. Conroy, F. Bonnetain, 2016, Health and Quality of Life Outcomes.

F. Fiteni, F. Bonnetain, N. Isambert, 2019, BMC Cancer.

Authors' response

F. Ghiringhelli, F. Bonnetain, B. Guiu, 2010, Gut.

Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study.

D. Vernerey, F. Bonnetain, J. Taieb, 2014 .

[Quality of life for patients treated for head and neck carcinoma].

P. Maingon, F. Bonnetain, P. Romanet, 2010, Cancer Radiothérapie.

Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study

M. Housset, S. Albert, F. Chabolle, 2015, Cancer medicine.

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

P. Bachellier, C. Borg, D. Vernerey, 2016, BMC Cancer.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

B. Chauffert, J. Cercueil, C. Lepage, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Impact of Response Shift on Time to Deterioration in Quality of Life Scores in Breast Cancer Patients

F. Guillemin, T. Conroy, F. Bonnetain, 2014, PloS one.

Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.

P. Rougier, F. Bonnetain, P. Hammel, 2015 .

Statistical challenges of quality of life and cancer: new avenues for future research

F. Guillemin, K. Baumstarck, A. Loundou, 2014, Expert review of pharmacoeconomics & outcomes research.

Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching.

P. Maingon, P. Arveux, P. Fumoleau, 2012, European journal of cancer.

ASTER 70s: Benefit of adjuvant chemotherapy for estrogen receptor-positive HER2-negative breast cancer in women over 70 according to genomic grade—A French GERICO/UCBG UNICANCER multicenter phase III trial.

F. André, H. Bonnefoi, V. Girre, 2012 .

Tilburg University International validation of the EORTC QLQ-ELD 14 questionnaire for assessment of health-related quality of life elderly patients with cancer

P. Fayers, W. Chie, J. Giesinger, 2013 .

Abstract OT3-3-10: ASTER 70s: Benefit of adjuvant chemotherapy for oestrogen receptor-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) multicentre phase III trial.

M. Lacroix-Triki, H. Bonnefoi, V. Girre, 2012 .

ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?

O. Mir, M. Lacroix-Triki, E. Blot, 2014 .

Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer.

Franck Bonnetain, P. Maingon, F. Bonnetain, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.

M. Moore, D. Goldstein, D. Vernerey, 2015 .

Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey.

F. Bonnetain, P. Hammel, R. Coriat, 2017, Bulletin du cancer.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

C. Tournigand, W. Scheithauer, T. Hickish, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD

C. Bascoul-Mollevi, Marion Savina, Amélie Anota, 2018, Comput. Methods Programs Biomed..

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial

M. Hebbar, F. Bonnetain, A. de Gramont, 2016, PloS one.

D. Goldstein, O. Bouché, F. Bonnetain, 2016, JAMA.

Survival end point reporting in randomized cancer clinical trials: a review of major journals.

S. Mathoulin-Pélissier, F. Bonnetain, S. Gourgou-Bourgade, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abdominal binders after laparotomy: review of the literature and French survey of policies

C. Mariette, F. Bonnetain, P. Rat, 2014, Hernia.

Predictive value of health-related quality of life on radiotherapy-related toxicities in patients with head and neck cancer

P. Maingon, F. Bonnetain, S. Maillard, 2023, Supportive Care in Cancer.

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

J. Taïeb, V. Boige, M. Hebbar, 2013, Journal of hepatology.

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.

F. Pruvot, M. Ychou, F. Bonnetain, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

M. Ducreux, P. Rougier, O. Bouché, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.